Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
COVID-19
Efficacy
Multiple sclerosis
Ocrelizumab
Safety
Treatment
Journal
Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403
Informations de publication
Date de publication:
15 08 2021
15 08 2021
Historique:
received:
18
03
2021
revised:
25
04
2021
accepted:
17
05
2021
pubmed:
28
5
2021
medline:
5
8
2021
entrez:
27
5
2021
Statut:
ppublish
Résumé
During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for ocrelizumab infusions in Relapsing Remitting Multiple Sclerosis (RRMS) patients according to the national recommendations. Out of the 83 RRMS patients whose infusion was scheduled between March and December 2020, 56 patients experienced a delay in treatment based on MS severity and SARS-CoV2 infection risk profile. In most cases, the immunophenotype was performed monthly to guide re-infusions. Specifically, B CD19 + cells repopulation rate was monitored. Mean infusion delay was 103,1 [SD 40,6] days, and none of the patients presented relapses or active disease at MRI at the end of the observation period. Treatment naïve status and the interval between immunophenotyping and the last ocrelizumab infusion were predictors of earlier B CD19 + cells repopulation. Two patients contracted SARS-CoV2 with complete recovery. Definitive data about Sars-Cov2 vaccine efficacy in patients treated with ocrelizumab are still lacking. Our findings suggest that a personalized treatment with a delayed infusion schedule does not compromise ocrelizumab short-term efficacy and may help to lengthen the therapeutic window for an effective response to SARS-CoV2 vaccine.
Identifiants
pubmed: 34044238
pii: S0022-510X(21)00195-7
doi: 10.1016/j.jns.2021.117501
pmc: PMC8133824
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
RNA, Viral
0
ocrelizumab
A10SJL62JY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117501Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
J Neurol. 2019 Jan;266(1):57-67
pubmed: 30377816
Mult Scler. 2021 Dec;27(14):2126-2136
pubmed: 33205695
JAMA Neurol. 2013 Sep 1;70(9):1110-7
pubmed: 23897062
Mult Scler Relat Disord. 2020 Sep;44:102279
pubmed: 32645640
Nat Rev Neurol. 2015 Jul;11(7):379-89
pubmed: 26032396
Mult Scler Relat Disord. 2021 Jan;47:102642
pubmed: 33321356
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Mult Scler Relat Disord. 2020 Jul;42:102120
pubmed: 32315980
N Engl J Med. 2008 Feb 14;358(7):676-88
pubmed: 18272891
Clin Exp Immunol. 2020 Nov;202(2):149-161
pubmed: 32671831
Ann Neurol. 2020 Jun;87(6):794-797
pubmed: 32383812
Mult Scler Relat Disord. 2021 Feb;48:102704
pubmed: 33370649
Mult Scler. 2020 Oct;26(12):1519-1531
pubmed: 31573386
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 25;7(5):
pubmed: 32587103